Amini, Ava P. http://orcid.org/0000-0002-8601-6040
Kirkpatrick, Jesse D. http://orcid.org/0000-0002-1487-9568
Wang, Cathy S. http://orcid.org/0000-0003-0910-4562
Jaeger, Alex M.
Su, Susan http://orcid.org/0000-0002-4909-7937
Naranjo, Santiago
Zhong, Qian
Cabana, Christina M.
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
Bhatia, Sangeeta N. http://orcid.org/0000-0002-1293-2097
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA14051)
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (P30-ES002109)
Virginia and D.K. Ludwig Fund for Cancer Research
Johnson and Johnson
U.S. Department of Health & Human Services | National Institutes of Health (T32GM007287)
National Science Foundation
Howard Hughes Medical Institute
Article History
Received: 22 November 2021
Accepted: 24 August 2022
First Online: 3 October 2022
Competing interests
: T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific and a co-founder of Dragonfly Therapeutics and T2 Biosystems; serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech, and Skyhawk Therapeutics; and is President of Break Through Cancer. T.J.’s laboratory currently receives funding from Johnson & Johnson and The Lustgarten Foundation, but these funds did not support the research described in this manuscript. S.N.B. reports compensation for cofounding, consulting for, and/or board membership in Glympse Bio, Satellite Bio, CEND Therapeutics, Catalio Capital, Intergalactic Therapeutics, Port Therapeutics, Vertex Pharmaceuticals, and Moderna, and receives sponsored research funding from Johnson & Johnson, Revitope, and Owlstone. Funds from Johnson & Johnson to S.N.B.’s laboratory supported the research described in this manuscript. The remaining authors declare no competing interests.